# The Perspective of Using Ischemic Tolerance in Clinical Practice

## TL;DR

This paper explores using ischemic tolerance, a natural protective mechanism, to treat ischemia-reperfusion injuries in clinical settings.

## Contribution

It proposes transferring ischemic tolerance via activated blood plasma from healthy donors to patients unable to build their own tolerance.

## Key findings

- Ischemic tolerance effectors can be transferred through blood plasma.
- Activated plasma may treat ischemia-reperfusion injuries in patients unable to self-generate tolerance.
- Experimental evidence suggests this method could be effective in clinical practice.

## Abstract

Ischemic–reperfusion injury represents an extremely serious problem in the human population. It mainly affects the elderly population and currently used treatments have poor results. However, in nature there is a much more effective and relatively well-studied mechanism known as the ischemic tolerance phenomenon. If an organism is exposed to adverse conditions that do not destroy it, it responds by producing substances capable of protecting it from severe damage or death in the event of a repeated encounter with the same or a different dangerous environment. The problem with its use in the clinic is that its effectiveness decreases in the elderly and is practically lost with associated diseases and their concurrent treatment. Based on experimental animal studies and findings, it can be assumed that the activation of full tolerance—through successive exposure to two stressors in young, healthy individuals—will result in the formation of effectors of tolerance, which are spread throughout the body through the blood. Blood plasma thus activated and administered to a recipient who is unable to otherwise acquire tolerance, should be used as an immediate treatment for ischemia–reperfusion injury and a wide range of impending injuries in all individuals, since activated plasma contains effectors of ischemic tolerance. The purpose of this work is to show the possibilities of using ischemic tolerance in the clinical practice. Complete tolerance can be transferred from young, healthy, unmedicated donors to patients who have lost their ability to build tolerance in their own bodies.